DGAP-News: Eckert&Ziegler to join Chinese-German Pharma Development Joint Venture
(firmenpresse) - DGAP-News: Eckert&Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Investment
Eckert&Ziegler to join Chinese-German Pharma Development Joint
Venture
22.07.2013 / 10:04
---------------------------------------------------------------------
Berlin, July 22, 2013. Berlin-based Eckert&Ziegler AG by its subsidiary
Eckert&Ziegler Radiopharma GmbH will acquire a minority interest in
OctreoPharm Sciences GmbH, a company specialized in radiopharmaceuticals
for nuclear medicine. OctreoPharm Sciences focuses on the clinical
development of new types of radiopharmaceuticals for diagnostics and
treatment in the field of oncology.
OctreoPharm Sciences has various peptides currently in pre-clinical
development as a potential solution for the detection of neuroendocrine
tumors using positron emission tomography (PET). Depending on the
radionuclide it is coupled with, it could be used both in diagnosing
(gallium-68) and treating (yttrium-90) such tumors. Clinical testing on
humans (phase I) is slated to begin towards the end of next year.
The global market volume for medicinal products for the diagnosis and
radiopharmaceutical treatment of neuroendocrine tumors is estimated at more
than EUR250 million per year. Neuroendocrine tumors are usually malignant
tumors affecting glandular cells in the lung and digestive system that
metastasize early.
In addition to Eckert&Ziegler AG, several Venture Capital Companies, a
number of industry experts and Chinese investor Shaanxi Xinyida Investment
Co. Ltd. also hold a stake in OctreoPharm Sciences, the investment totaling
in the double-digit millions.
With more than 600 employees, Eckert&Ziegler Strahlen- und Medizintechnik
AG (ISIN DE0005659700) is one of the world's largest providers of
components based on isotope technology for radiation therapy and nuclear
medicine.
If you have any questions, please contact:
Eckert&Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle(at)ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
22.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
222205 22.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.07.2013 - 10:04 Uhr
Sprache: Deutsch
News-ID 280281
Anzahl Zeichen: 8973
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler to join Chinese-German Pharma Development Joint Venture"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
